secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001437749-25-005477
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma Biotechnology reports Q4 GAAP net income $19.3M ($0.39 EPS); guides FY2025 net income $23-28M
--------------------------------------------------------------------------------

- Q4 product revenue net $54.4M (up from $53.2M YoY); full year $195.2M (down from $203.1M).
- GAAP net income $30.3M ($0.62/share) for FY2024 vs. $21.6M ($0.46) in FY2023.
- Non-GAAP adjusted net income $38.5M ($0.79/share) for FY2024 vs. $31.8M ($0.68) in FY2023.
- Cash and securities $101M at Dec 31, 2024; operating cash flow $38.9M for FY2024.
- FY2025 guidance: net product revenue $192-198M; net income $23-28M (excludes valuation allowance).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774925005477/0001437749-25-005477-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774925005477/pbyi20250224_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-005477

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer